Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease

Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial

“…It is thus, important to advocate for low-cost affordable treatment options for chronic care of CVD. The polypill has the advantage of being one pill instead of four, making it a less complex regimen which could promote more widespread use and greater adherence (45)(46)(47). The simplified treatment regimen and lower cost of the polypill relative to usual care further drives the polypill's dominance in our CEA.…”

Fixed‐dose combination therapy to reduce the growing burden of cardiovascular disease in low‐ and middle‐income countries: feasibility and challenges

“…The current literature is clear about the fact that polypills increase adherence to medication . Nonadherence to medication has been shown to be more prevalent in LMICs.…”

“…Another important point of action should be the advocacy for the adoption and use of polypills, which requires endorsement from national key opinion leaders and national bodies . For instance, the Spanish Society of Cardiology, together with various primary care associations, developed a consensus document for the use of polypills in the secondary prevention of CVD . Likewise, other societies such as the European Society of Hypertension took position towards polypills’ usage in clinical care .…”

“…The current literature is clear about the fact that polypills increase adherence to medication. [10][11][12][13][14][15][16][17][18][21][22][23] Nonadherence to medication has been shown to be more prevalent in LMICs. For instance, the PURE (Prospective Urban Rural Epidemiology) study demonstrated that in LMICs, only 3% of participants with a history of coronary heart disease or stroke were still taking drugs for secondary prevention of CVD 5 years post-event.…”

“…13 For instance, the Spanish Society of Cardiology, together with various primary care associations, developed a consensus document for the use of polypills in the secondary prevention of CVD. 23 Likewise, other societies such as the European Society of Hypertension took position towards polypills' usage in clinical care. 22 These examples should be copied by LMIC scientific societies to support polypill implementation and manipulation in this part of the world.…”